Tirzepatide vs. Semaglutide: What’s the Difference?
A clinically grounded comparison of the two leading GLP-1 weight loss medications — how they work, what results to expect, side effects, cost, and which may be right for you.
Find Out Which Is Right for You →Quick Answer: Semaglutide (Wegovy/Ozempic) is a GLP-1 receptor agonist producing average weight loss of ~15% of body weight. Tirzepatide (Zepbound/Mounjaro) is a dual GIP/GLP-1 receptor agonist producing average weight loss of 15–22%. Both are FDA-approved, physician-prescribed medications. Tirzepatide generally produces superior outcomes in clinical trials; the right choice depends on your individual health profile and goals.
Tirzepatide vs. Semaglutide: Side-by-Side Comparison
| Category | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | ||
| Drug class | GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist |
| Receptors targeted | GLP-1 only | GLP-1 & GIP |
| Brand Names | ||
| Obesity indication | Wegovy | Zepbound |
| Diabetes indication | Ozempic | Mounjaro |
| Oral option | Rybelsus (diabetes only) | Oral tirzepatide (select telehealth programs) |
| Clinical Results | ||
| Avg. weight loss | ~15% body weight (STEP trials, 68 wks) | 15–22% body weight (SURMOUNT trials, 72 wks) |
| Trial program | STEP 1–5 | SURMOUNT 1–4 |
| FDA approval (obesity) | Wegovy — 2021 | Zepbound — 2023 |
| Administration | ||
| Injection frequency | Once weekly | Once weekly |
| Oral format | Rybelsus (diabetes); not for obesity | Available through select programs |
| Dose range | 0.25 mg → 2.4 mg (Wegovy) | 2.5 mg → 15 mg (Zepbound) |
| Cost (Without Insurance) | ||
| Brand-name retail | ~$1,300–$1,600/month | ~$1,000–$1,300/month |
| Compounded (telehealth) | More affordable via licensed programs | More affordable via licensed programs |
| HSA/FSA eligible | Typically yes | Typically yes |
| Common Side Effects | ||
| GI effects | Nausea, diarrhea, constipation, vomiting | Nausea, diarrhea, constipation, vomiting |
| Onset of side effects | Dose-dependent; typically early in treatment | Dose-dependent; typically early in treatment |
| Availability | ||
| Telehealth access | Yes — widely available | Yes — available through select programs |
| Track record | Longer (approved 2021) | Newer (approved 2023) |
Data sourced from FDA prescribing information and published STEP/SURMOUNT clinical trial results. Individual results may vary. Table last updated May 2026.
How Each Medication Works
GLP-1 Receptor Agonist
- Mimics the GLP-1 hormone produced naturally in the gut after eating
- Binds to GLP-1 receptors in the brain, pancreas, and GI tract
- Suppresses appetite and reduces food cravings
- Slows gastric emptying — food stays in the stomach longer
- Improves insulin secretion and blood sugar regulation
- Single-pathway mechanism; well-established safety profile
Dual GIP + GLP-1 Receptor Agonist
- Activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors
- GIP activation may enhance fat metabolism and further reduce appetite
- Dual-pathway mechanism produces greater hormonal signaling than GLP-1 alone
- Slows gastric emptying and suppresses appetite via two complementary pathways
- Improves insulin sensitivity and metabolic function
- Produces greater average weight loss than semaglutide in clinical comparisons
Possible Benefits of Each Medication
Potential Benefits
- Average weight loss of ~15% of body weight over 68 weeks (STEP trials)
- Significant reduction in appetite and food cravings
- Improved blood sugar control (beneficial for patients with type 2 diabetes)
- Cardiovascular risk reduction (SELECT trial data)
- Longer clinical track record — approved for obesity since 2021
- Widely available through telehealth programs
Potential Benefits
- Average weight loss of 15–22% of body weight over 72 weeks (SURMOUNT trials)
- Superior average outcomes vs. semaglutide in direct comparisons
- Dual-mechanism action may produce stronger appetite suppression
- Improved insulin sensitivity and metabolic markers
- Oral format available through select physician-guided programs
- FDA-approved for obesity (Zepbound) since 2023
Possible benefits are based on published clinical trial data. Individual results vary. These medications should only be used under physician supervision as part of a comprehensive weight management program.
Not Sure Which Medication Is Right for You?
A DietsMD board-certified physician will evaluate your health history, goals, and eligibility — and recommend the right GLP-1 medication and dose for your individual profile.
Start Your Consultation →Potential Side Effects
Both medications share a similar side effect profile due to their shared GLP-1 mechanism. Side effects are typically mild, dose-dependent, and most common during the dose escalation phase.
Common Side Effects (Both Medications)
- Nausea
- Diarrhea
- Constipation
- Vomiting
- Decreased appetite
- Fatigue (early in treatment)
- Abdominal discomfort
Less Common / Serious Risks
- Pancreatitis (rare)
- Gallbladder disease
- Hypoglycemia (especially with other diabetes medications)
- Heart rate increase
- Injection site reactions
- Thyroid C-cell tumors (animal studies; contraindicated in MTC/MEN2 history)
Who May Qualify for GLP-1 Weight Loss Medications?
Eligibility for semaglutide or tirzepatide is determined by a licensed physician based on your individual health profile. General clinical criteria include:
Typical Eligibility Criteria
- BMI ≥ 30 (obesity), or
- BMI ≥ 27 with at least one weight-related condition (e.g., hypertension, type 2 diabetes, sleep apnea)
- No personal or family history of MTC or MEN2
- No active pancreatitis
- Not pregnant or planning to become pregnant
- Commitment to a physician-guided program
Who Should Discuss With a Physician
- Patients with a history of eating disorders
- Patients on insulin or other diabetes medications (hypoglycemia risk)
- Patients with kidney or liver disease
- Patients with a history of gallbladder disease
- Patients with cardiovascular conditions
- Patients currently taking other prescription medications
The only way to determine your eligibility is through a physician evaluation. Start your DietsMD consultation to get started.
Get Both Options Through DietsMD — Physician-Guided, Fully Online
DietsMD is one of the only telehealth programs offering both semaglutide and tirzepatide — including oral tirzepatide — under direct board-certified MD oversight. Your physician will evaluate your health history and recommend the right medication, dose, and titration schedule for your goals.
- ✔ Semaglutide & tirzepatide (injectable and oral) available
- ✔ Board-certified MD prescribing and monitoring — not just NPs
- ✔ All-inclusive transparent pricing — no hidden fees
- ✔ Fully online — evaluation, prescription, and delivery from home
- ✔ Ongoing dose titration and physician check-ins included
- ✔ HIPAA-compliant — HSA/FSA eligible
Frequently Asked Questions
What is the main difference between tirzepatide and semaglutide?
Semaglutide activates only the GLP-1 receptor. Tirzepatide activates both the GLP-1 and GIP receptors simultaneously, which may produce greater appetite suppression and weight loss. Clinical trials show tirzepatide produces average weight loss of 15–22% of body weight vs. ~15% for semaglutide.
Is tirzepatide stronger than semaglutide?
In head-to-head clinical trials, tirzepatide produced greater average weight loss than semaglutide. However, individual response varies based on health history, dose, and adherence. A licensed physician can help determine which medication may be more appropriate for your goals.
What are the brand names for semaglutide and tirzepatide?
Semaglutide is sold as Wegovy (obesity) and Ozempic (type 2 diabetes). Tirzepatide is sold as Zepbound (obesity) and Mounjaro (type 2 diabetes). Compounded versions of both are available through licensed telehealth programs.
Do semaglutide and tirzepatide have the same side effects?
Both medications share similar GI-related side effects including nausea, diarrhea, constipation, and vomiting, which are typically mild and dose-dependent. Both carry rare but serious risks including pancreatitis and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2. Always discuss your full medical history with a physician before starting either medication.
Which is more affordable — semaglutide or tirzepatide?
Brand-name Wegovy (semaglutide) costs approximately $1,300–$1,600/month without insurance. Brand-name Zepbound (tirzepatide) costs approximately $1,000–$1,300/month. Compounded versions available through telehealth programs like DietsMD are significantly more affordable, with all-inclusive transparent pricing.
Can I switch from semaglutide to tirzepatide?
Switching between GLP-1 medications is possible and sometimes recommended if a patient has a suboptimal response. This should always be done under physician supervision with appropriate dose adjustment and monitoring. Talk to a DietsMD physician about your options.
Is oral tirzepatide available?
Yes. Oral tirzepatide is available through select physician-guided telehealth programs, including DietsMD, for patients who prefer to avoid injections. Eligibility is determined by a licensed physician after a medical evaluation. Learn more about oral tirzepatide.
Ready to Start Your GLP-1 Weight Loss Journey?
DietsMD physicians will evaluate your health history and recommend the right medication — semaglutide or tirzepatide — for your individual goals. Fully online, all-inclusive pricing, no hidden fees.
Get Started with DietsMD →